Endocrinology and Metabolism

Original Articles

Adrenal gland Big Data Articles (National Health Insurance Service Database)
Mortality and Severity of Coronavirus Disease 2019 in Patients with Long-Term Glucocorticoid Therapy: A Korean Nationwide Cohort Study: Eu Jeong Ku, Keeho Song, Kyoung Min Kim, Gi Hyeon Seo, Soon Jib Yoo; Endocrinol Metab. 2023;38(2):253-259. Published online March 21, 2023; DOI: https://doi.org/10.3803/EnM.2022.1607

6,674 View
127 Download
5 Web of Science
5 Crossref

Background
The severity of coronavirus disease 2019 (COVID-19) among patients with long-term glucocorticoid treatment (LTGT) has not been established. We aimed to evaluate the association between LTGT and COVID-19 prognosis.
Methods
A Korean nationwide cohort database of COVID-19 patients between January 2019 and September 2021 was used. LTGT was defined as exposure to at least 150 mg of prednisolone (≥5 mg/day and ≥30 days) or equivalent glucocorticoids 180 days before COVID-19 infection. The outcome measurements were mortality, hospitalization, intensive care unit (ICU) admission, length of stay, and mechanical ventilation.
Results
Among confirmed patients with COVID-19, the LTGT group (n=12,794) was older and had a higher proportion of comorbidities than the control (n=359,013). The LTGT group showed higher in-hospital, 30-day, and 90-day mortality rates than the control (14.0% vs. 2.3%, 5.9% vs. 1.1%, and 9.9% vs. 1.8%, respectively; all P<0.001). Except for the hospitalization rate, the length of stay, ICU admission, and mechanical ventilation proportions were significantly higher in the LTGT group than in the control (all P<0.001). Overall mortality was higher in the LTGT group than in the control group, and the significance remained in the fully adjusted model (odds ratio [OR], 5.75; 95% confidence interval [CI], 5.31 to 6.23) (adjusted OR, 1.82; 95% CI, 1.67 to 2.00). The LTGT group showed a higher mortality rate than the control within the same comorbidity score category.
Conclusion
Long-term exposure to glucocorticoids increased the mortality and severity of COVID-19. Prevention and early proactive measures are inevitable in the high-risk LTGT group with many comorbidities.

Citations

Citations to this article as recorded by

Hormonal Implications of SARS‐CoV‐2: A Review of Endocrine Disruptions
Aliya Yskak, Yevgeniy Sokharev, Kuanysh Zhumalynov, Elizaveta Koneva, Natalia Afanasyeva, Dmitri Borodulin, Dmitrii Babaskin, Almabek Nugmanov, Murat Nurushev, Vadim Chashkov, Gianmarco Ferrara
Scientifica.2025;[Epub] CrossRef
Association Between Pre-hospital Medication Use and Outcomes in Patients Hospitalized for COVID-19 Pneumonia: A Multicenter Observational Study in the Netherlands
Letao Li, Joyce Goris-de Geus, Iris de Leeuw, Floortje Kanits, Jaccoline Zegers, Arjan van Zadelhoff, Noud Buenen, Thijs Clemens David Rettig, Monique P. L Hoir, Geerke Duijzer, Johanna Marianne Geleijnse, Henrik Endeman
Cureus.2025;[Epub] CrossRef
Outpatient glucocorticoid use and COVID-19 outcomes: a population-based study
Almudena Rodríguez-Fernández, Irene Visos-Varela, Maruxa Zapata-Cachafeiro, Samuel Pintos-Rodríguez, Rosa M. García-Álvarez, Teresa M. Herdeiro, María Piñeiro-Lamas, Adolfo Figueiras, Ángel Salgado-Barreira, Rosendo Bugarín-González, Eduardo Carracedo-Mar
Inflammopharmacology.2024; 32(4): 2305. CrossRef
Glucocorticoids as a Double-Edged Sword in the Treatment of COVID-19: Mortality and Severity of COVID-19 in Patients Receiving Long-Term Glucocorticoid Therapy
Eun-Hee Cho
Endocrinology and Metabolism.2023; 38(2): 223. CrossRef
Pituitary Diseases and COVID-19 Outcomes in South Korea: A Nationwide Cohort Study
Jeonghoon Ha, Kyoung Min Kim, Dong-Jun Lim, Keeho Song, Gi Hyeon Seo
Journal of Clinical Medicine.2023; 12(14): 4799. CrossRef

Adrenal Gland Big Data Articles (National Health Insurance Service Database)
Epidemiology and Long-Term Adverse Outcomes in Korean Patients with Congenital Adrenal Hyperplasia: A Nationwide Study: Jung Hee Kim, Sunkyu Choi, Young Ah Lee, Juneyoung Lee, Sin Gon Kim; Endocrinol Metab. 2022;37(1):138-147. Published online February 28, 2022; DOI: https://doi.org/10.3803/EnM.2021.1328

8,834 View
208 Download
24 Web of Science
24 Crossref

Abstract PDF PubReader ePub

Background
Previous studies on the epidemiology and complications of congenital adrenal hyperplasia (CAH) were conducted in Western countries and in children/adolescents. We aimed to explore the epidemiology of CAH, as well as the risk of comorbidities and mortality, in a Korean nationwide case-control study.
Methods
CAH patients (n=2,840) were included between 2002 and 2017 from the National Health Insurance Service database and the Rare Intractable Disease program. CAH patients were compared, at a 1:10 ratio, with age-, sex-, and index year-matched controls (n=28,400).
Results
The point prevalence of CAH patients in Korea was 1 in 18,745 persons in 2017. The annual incidence rate declined between 2003 and 2017 from 3.25 to 0.41 per 100,000 persons. CAH patients were at elevated risk for cardiovascular disease (odds ratio [OR], 1.6; 95% confidence interval [CI], 1.4 to 1.9), stroke (OR, 1.7; 95% CI, 1.3 to 2.0), diabetes mellitus (OR, 2.8; 95% CI, 2.6 to 3.1), dyslipidemia (OR, 2.4; 95% CI, 2.2 to 2.6), and psychiatric disorders (OR, 1.5; 95% CI, 1.3 to 1.6). Fracture risk increased in CAH patients aged over 40 years (OR, 1.4; 95% CI, 1.1 to 1.7). CAH patients were at higher risk of mortality than controls (hazard ratio, 1.6; 95% CI, 1.3 to 2.0).
Conclusion
Our nationwide study showed a recent decline in the incidence of CAH and an elevated risk for cardiovascular, metabolic, skeletal, and psychiatric disorders in CAH patients. Lifelong management for comorbidity risk is a crucial component of treating CAH patients.

Citations

Citations to this article as recorded by

Clinical tools for evaluating congenital adrenal hyperplasia in resource-limited hospitals: a study at a tertiary hospital in Saudi Arabia
Daniah Alhazmi, Azzam Alabdulqader, Shahad Almeqbel, Raghad Alhuthil, Afaf Alsagheir
Frontiers in Endocrinology.2026;[Epub] CrossRef
Cardiometabolic Aspects of Congenital Adrenal Hyperplasia
Robert Krysiak, Hedi L Claahsen-van der Grinten, Nicole Reisch, Philippe Touraine, Henrik Falhammar
Endocrine Reviews.2025; 46(1): 80. CrossRef
Prevalence of Psychiatric Comorbidities in Females With Classic Congenital Adrenal Hyperplasia
Behzad Sorouri Khorashad, Oumaima Kaabi, Melissa D Gardner, Darios Getahun, Michael Goodman, Timothy L Lash, Peter A Lee, Joshua May, Courtney McCracken, Maria Muzik, Suma Vupputuri, Rami Yacoub, David E Sandberg
The Journal of Clinical Endocrinology & Metabolism.2025; 110(8): e2562. CrossRef
Glucocorticoid therapy in classic congenital adrenal hyperplasia: traditional and new treatment paradigms
Irina Bancos, Hyunwoo Kim, Henry K. Cheng, Mariam Rodriguez-Lee, Helen Coope, Samantha Cicero, Hannah Goldsmith, Vivian H. Lin, George S. Jeha
Expert Review of Endocrinology & Metabolism.2025; 20(1): 33. CrossRef
Clinical Manifestations and Challenges in Adolescent and Adult Females With Classic Congenital Adrenal Hyperplasia Due to 21-Hydroxylase Deficiency
Hedvig Engberg, Anna Nordenström, Angelica Lindén Hirschberg
The Journal of Clinical Endocrinology & Metabolism.2025; 110(Supplement): S37. CrossRef
Metabolic Syndrome Spectrum in Children with Classic Congenital Adrenal Hyperplasia—A Comprehensive Review
Sanja Panic Zaric, Tatjana Milenkovic, Sladjana Todorovic, Katarina Mitrovic, Dimitrije Cvetkovic, Maja Cehic, Jelena Vekic, Katja Dumic, Rade Vukovic
Metabolites.2025; 15(2): 89. CrossRef
Long-term outcomes of congenital adrenal hyperplasia due to 21-hydroxylase deficiency: a retrospective study from a tertiary care center in Saudi Arabia
Haneen Aldalaan, Afaf Alsagheir, Nujud Alghamdi, Raghad Alhuthil, Maha Almslam, Mohamed H. Al-Hamed
Frontiers in Endocrinology.2025;[Epub] CrossRef
The epidemiology of disorders of sex development
Agnethe Berglund, Simon Chang, Marie Lind-Holst, Kirstine Stochholm, Claus Højbjerg Gravholt
Best Practice & Research Clinical Endocrinology & Metabolism.2025; 39(4): 102002. CrossRef
Causal associations between congenital adrenal hyperplasia and neuropsychiatric conditions- a Mendelian Randomization Study
Yang Liu, Xiaokun Gang, Yuan Gao, Guixia Wang
Endocrine.2025; 89(1): 291. CrossRef
Epidemiology and clinical outcomes of clinically suspected multiple endocrine neoplasia type 1 in South Korea: a nationwide cohort study
Kyoung Jin Kim, Min Heui Yu, Yoon-a Hwang, Shinje Moon, Namki Hong, Yumie Rhee
Frontiers in Endocrinology.2025;[Epub] CrossRef
Non-classical congenital adrenal hyperplasia: current insights into clinical implications, diagnosis and treatment
Paola Loli, Sara Menotti, Luigi di Filippo, Andrea Giustina
Endocrine.2025; 90(1): 1. CrossRef
Increased mortality in primary adrenal insufficiency: a systematic review and meta-analysis
Konstantinos Dalakas, Francesca Allosso, Christian Basile, Ragnhildur Bergthorsdottir, Dimitrios Chantzichristos, Eva Hessman, Bright I Nwaru, Emanuele Bobbio, Daniela Pasquali, Gudmundur Johannsson, Daniela Esposito
European Journal of Endocrinology.2025; 193(4): S53. CrossRef
Exploration of the potential of genomic editing in the treatment of congenital adrenal hyperplasia
Lara E. Graves, Sharntie Christina, Kathryn L. Mullany, Ian E. Alexander, Henrik Falhammar
Frontiers in Endocrinology.2025;[Epub] CrossRef
Long‐term health consequences of congenital adrenal hyperplasia
Riccardo Pofi, Xiaochen Ji, Nils P. Krone, Jeremy W. Tomlinson
Clinical Endocrinology.2024; 101(4): 318. CrossRef
Hyperandrogenism and Cardiometabolic Risk in Pre- and Postmenopausal Women—What Is the Evidence?
Angelica Lindén Hirschberg
The Journal of Clinical Endocrinology & Metabolism.2024; 109(5): 1202. CrossRef
Predictors of Cardiovascular Morbidities in Adults With 21-Hydroxylase Deficiency Congenital Adrenal Hyperplasia
Suranut Charoensri, Richard J Auchus
The Journal of Clinical Endocrinology & Metabolism.2024; 109(3): e1133. CrossRef
Case report: Development of central precocious puberty in a girl with late-diagnosed simple virilizing congenital adrenal hyperplasia complicated with Williams syndrome
Eun Young Joo, Myung Ji Yoo, Su Jin Kim, Woori Jang, Ji-Eun Lee
Frontiers in Endocrinology.2024;[Epub] CrossRef
Proof of concept for a superior therapeutic index of corticosterone compared with hydrocortisone in patients with congenital adrenal hyperplasia
Catriona J Kyle, Luke D Boyle, Mark Nixon, Natalie Z M Homer, Joanna P Simpson, Alison Rutter, Lynne E Ramage, Alexandra Kelman, Ellen Marie Freel, Ruth Andrew, Brian R Walker, Roland H Stimson
European Journal of Endocrinology.2024; 191(6): 535. CrossRef
Анализ распространенности и заболеваемости надпочечниковой недостаточностью в мире
М. Ю. Юкина, Н. Ф. Нуралиева, Е. А. Трошина
Ateroscleroz.2023; 18(4): 426. CrossRef
Big Data Research in the Field of Endocrine Diseases Using the Korean National Health Information Database
Sun Wook Cho, Jung Hee Kim, Han Seok Choi, Hwa Young Ahn, Mee Kyoung Kim, Eun Jung Rhee
Endocrinology and Metabolism.2023; 38(1): 10. CrossRef
Long-term cardiometabolic morbidity in young adults with classic 21-hydroxylase deficiency congenital adrenal hyperplasia
Beatrice Righi, Salma R. Ali, Jillian Bryce, Jeremy W. Tomlinson, Walter Bonfig, Federico Baronio, Eduardo C. Costa, Guilherme Guaragna-Filho, Guy T’Sjoen, Martine Cools, Renata Markosyan, Tania A. S. S. Bachega, Mirela C. Miranda, Violeta Iotova, Henrik
Endocrine.2023; 80(3): 630. CrossRef
Serum steroid profile captures metabolic phenotypes in adults with classic congenital adrenal hyperplasia
Chang Ho Ahn, Jaeyoon Shim, Han Na Jang, Young Ah Lee, Sang-Won Lee, Man Ho Choi, Jung Hee Kim
The Journal of Steroid Biochemistry and Molecular Biology.2023; 234: 106374. CrossRef
Multiplexed Serum Steroid Profiling Reveals Metabolic Signatures of Subtypes in Congenital Adrenal Hyperplasia
Jaeyoon Shim, Chang Ho Ahn, Seung Shin Park, Jongsung Noh, Chaelin Lee, Sang Won Lee, Jung Hee Kim, Man Ho Choi
Journal of the Endocrine Society.2023;[Epub] CrossRef
Long-Term Outcomes of Congenital Adrenal Hyperplasia
Anna Nordenström, Svetlana Lajic, Henrik Falhammar
Endocrinology and Metabolism.2022; 37(4): 587. CrossRef

Clinical Study
Characteristics of Immune-Related Thyroid Adverse Events in Patients Treated with PD-1/PD-L1 Inhibitors: Jee Hee Yoon, A Ram Hong, Hee Kyung Kim, Ho-Cheol Kang; Endocrinol Metab. 2021;36(2):413-423. Published online April 6, 2021; DOI: https://doi.org/10.3803/EnM.2020.906

11,658 View
279 Download
42 Web of Science
39 Crossref

Abstract PDF Supplementary Material PubReader ePub

Background
Thyroid immune-related adverse events (IRAEs) have been reported in patients treated with programmed cell death protein-1 (PD-1) and programmed cell death protein-ligand 1 (PD-L1) inhibitors. We investigated the incidence and clinical course of PD-1/PD-L1 inhibitor-induced thyroid IRAEs, and identified predictable clinical risk factors of thyroid IRAEs, in particular, overt hypothyroidism (OH).
Methods
We retrospectively reviewed the medical records of 325 cancer patients receiving PD-1/PD-L1 inhibitor in a tertiary referral center.
Results
A total of 50.5% (164/325) of patients experienced at least one abnormal thyroid function following PD-1/PD-L1 inhibitor. Eighty-four patients (51.2%) of them recovered to normal thyroid function during follow-up. In overall population, 25 patients (7.7%) required thyroid hormone replacement therapy due to PD-1/PD-L1 inhibitor-induced OH. Patients who progressed to OH showed significantly higher baseline thyroid stimulating hormone level and longer duration of PD-1/PD-L1 inhibitor therapy than those without thyroid dysfunction or OH (both P<0.001). Median time interval to the development of OH was 3 months after the therapy. OH was significantly associated with positive anti-thyroid peroxidase antibody at baseline and anti-thyroglobulin antibody during the therapy than those without thyroid dysfunction or OH (P=0.015 and P=0.005, respectively). We observed no patients with OH who were able to stop levothyroxine replacement after the cessation of PD-1/PD-L1 inhibitor therapy.
Conclusion
PD-1/PD-L1 inhibitor-induced thyroid dysfunctions are considerably reversible; however, OH is irreversible requiring levothyroxine replacement even after stopping the therapy. Positive thyroid autoantibodies may predict the progression to OH.

Citations

Citations to this article as recorded by

Perioperative preparation for head and neck cancer patients receiving immunotherapy
Shao-Chun Wu, Kuan-Hao Liao, Pi-Chieh Lin, Ching-Hua Hsieh
Asian Journal of Surgery.2026; 49(2): 652. CrossRef
Risk factors of immune-related endocrine toxicities in non-small cell lung cancer patients treated with pembrolizumab and its impact on patient outcomes: a multicenter retrospective study
Haoting Zhang, Jing Zheng, Chenyi Ren, Chenlin Ye, Xiaoyu Wu, Xiaodong Lv, Yuping Li, Jianya Zhou, Jianying Zhou
BMC Pulmonary Medicine.2025;[Epub] CrossRef
Thyroid dysfunction as a predictor of PD- 1/PD-L1 inhibitor efficacy in advanced lung cancer
Yanling Wang, Xiaoping Ma, Jia Ma, Jing Li, Zhiyi Lin, Wei Gao, Ping Gong, Ping Dai
BMC Cancer.2025;[Epub] CrossRef
Pembrolizumab-Induced Thyroid Storm in a Patient With Triple-Negative Breast Cancer
Sobrina S. Mohammed, Eun Young Park, Reda Asad, Shourya Tadisina
AACE Endocrinology and Diabetes.2025; 12(2): 107. CrossRef
Optimal Levothyroxine Dosing Strategy for Immune Checkpoint Inhibitor-related Hypothyroidism: A Retrospective Study
Ya Gao, Chunxia Du, Yan Xu, Xinqi Cheng, Haitao Zhao, Fang Jiang, Ninghai Cheng, Yang Xiang, Yuelun Zhang, Yuanmeng Li, He Liu, Xiaofeng Chai, Xiaolan Lian, Weigang Zhao, Naishi Li
The Journal of Clinical Endocrinology & Metabolism.2025; 110(12): 3342. CrossRef
Complete remission in PD-L1 high expression advanced gastric cancer patient with PD-L1 immunotherapy and chemotherapy integration treatment strategy: a case report
Xiaopeng Yu, Wenwen Zhao, Qingqing Feng, Jin Tian, Lili Zhao, Jun Xiao, Hongmei Wei
Frontiers in Oncology.2025;[Epub] CrossRef
Changes in thyroid hormone levels indicate immunotherapy efficacy in gastric cancer
Min Xiao, Lan Qian, Qiu Zhao, Jian Ma, Qianxiao Li, Qian Liu, Zhiyan Bi
Oncology Letters.2025; 30(1): 1. CrossRef
Development and validation of a nomogram for predicting immune-related thyroid dysfunction during immunotherapy in non-small cell lung cancer: a prospective cohort study in China
Qianjie Xu, Yuliang Yuan, Xiaosheng Li, Lulu Wang, Wei Zhou, Zuhai Hu, Haike Lei, Yongzhong Wu
Frontiers in Immunology.2025;[Epub] CrossRef
Incidence of thyroid adverse events following immune checkpoint inhibitor treatment in patients with baseline positive thyroid antibodies: a systematic review and meta-analysis
Hui Yu, Qichao Chen, Wenbing Hu, Yuanhao Chen, Hui Ming
Frontiers in Oncology.2025;[Epub] CrossRef
Risk factors for endocrinological immune-related adverse events in patients with renal cell carcinoma treated with immune checkpoint inhibitors
Nicola Marrano, Mariangela Caporusso, Carlo Ganini, Andrea Borraccino, Angelo Cignarelli, Sebastio Perrini, Luigi Laviola, Camillo Porta, Francesco Giorgino, Annalisa Natalicchio
Journal of Endocrinological Investigation.2025; 49(2): 399. CrossRef
Thyroid Dysfunction after Atezolizumab and Bevacizumab Is Associated with Favorable Outcomes in Hepatocellular Carcinoma
Young Shin Song, Hannah Yang, Beodeul Kang, Jaekyung Cheon, Ilhwan Kim, Hyeyeong Kim, Won Suk Lee, Yun Beom Sang, Sanghoon Jung, Ho Yeong Lim, Vincent E. Gaillard, Chan Kim, Hong Jae Chon
Liver Cancer.2024; 13(1): 89. CrossRef
Thyroid dysfunction (TD) induced by PD-1/PD-L1 inhibitors in advanced lung cancer
Yanling Wang, Xiaoxuan Yang, Jia Ma, Shenglan Chen, Ping Gong, Ping Dai
Heliyon.2024; 10(5): e27077. CrossRef
Non-Invasive Predictive Biomarkers for Immune-Related Adverse Events Due to Immune Checkpoint Inhibitors
Ben Ponvilawan, Abdul Wali Khan, Janakiraman Subramanian, Dhruv Bansal
Cancers.2024; 16(6): 1225. CrossRef
Changes in TgAb and TPOAb titers are greater in thyrotoxicosis than isolated hypothyroidism induced by PD-1 blockade
Ayana Yamagami, Shintaro Iwama, Tomoko Kobayashi, Xin Zhou, Yoshinori Yasuda, Takayuki Okuji, Masaaki Ito, Tetsushi Izuchi, Masahiko Ando, Takeshi Onoue, Takashi Miyata, Mariko Sugiyama, Daisuke Hagiwara, Hidetaka Suga, Ryoichi Banno, Hiroshi Arima
Endocrine Journal.2024; 71(5): 515. CrossRef
Autoantibody-positivity before and seroconversion during treatment with anti-PD-1 is associated with immune-related adverse events in patients with melanoma
Jessica S W Borgers, Tineke J van Wesemael, Kyra A Gelderman, Theo Rispens, Els M E Verdegaal, Dirk J A R Moes, Catharina M Korse, Ellen Kapiteijn, Marij J P Welters, Sjoerd H van der Burg, Winan J van Houdt, Johannes V van Thienen, John B A G Haanen, Dia
Journal for ImmunoTherapy of Cancer.2024; 12(6): e009215. CrossRef
Development and Validation of a Prediction Model for Thyroid Dysfunction in Patients During Immunotherapy
Qian Wang, Tingting Wu, Ru Zhao, Yuanqin Li, Xuetao Chen, Shanmei Shen, Xiaowen Zhang
Endocrine Practice.2024; 30(10): 943. CrossRef
Perioperative toripalimab plus neoadjuvant chemotherapy might improve outcomes in resectable esophageal cancer: an interim analysis of a phase III randomized clinical trial
Yan Zheng, Guanghui Liang, Dongfeng Yuan, Xianben Liu, Yufeng Ba, Zimin Qin, Sining Shen, Zhenxuan Li, Haibo Sun, Baoxing Liu, Quanli Gao, Peng Li, Zongfei Wang, Shilei Liu, Jianping Zhu, Haoran Wang, Haibo Ma, Zhenzhen Liu, Fei Zhao, Jun Zhang, He Zhang,
Cancer Communications.2024; 44(10): 1214. CrossRef
Biomarkers in the early stage of PD-1 inhibitor treatment have shown superior predictive capabilities for immune-related thyroid dysfunction
Jinyu Liu, Mengli Chen, Shu Li, Le Cai, Liang Ma, Qiuliang Yang, Xiaoxuan Zhang, Nan Bai, Xiaodong Wu, Zhihui Tang, Tianlin Wang
Frontiers in Immunology.2024;[Epub] CrossRef
Immune checkpoint inhibitors-related thyroid dysfunction: influencing factor analysis, prediction model development, and management strategy proposal
Xinya Li, Zaiwei Song, Yixuan Chen, Jingjing Wu, Dan Jiang, Zhen Zhang, Zeyuan Wang, Rongsheng Zhao
Cancer Immunology, Immunotherapy.2024;[Epub] CrossRef
Serologic predictors of thyroid immune-related adverse events during immune checkpoint inhibitors therapy: a retrospective cohort study
Anastasia A. Glibka, Natalia V. Mazurina, Ksenia A. Sarantseva, Galina Y. Kharkevich, Mikhail V. Volkonskii, Alina R. Elfimova, Ekaterina A. Troshina
Almanac of Clinical Medicine.2024; 52(7): 385. CrossRef
Implication of the Gut Microbiome and Microbial-Derived Metabolites in Immune-Related Adverse Events: Emergence of Novel Biomarkers for Cancer Immunotherapy
David Dora, Syeda Mahak Zahra Bokhari, Kenan Aloss, Peter Takacs, Juliane Zsuzsanna Desnoix, György Szklenárik, Patrick Deniz Hurley, Zoltan Lohinai
International Journal of Molecular Sciences.2023; 24(3): 2769. CrossRef
Immune checkpoint inhibitor-associated toxicity in advanced non-small cell lung cancer: An updated understanding of risk factors
Xiangxiao Hu, Lina Wang, Bin Shang, Junren Wang, Jian Sun, Bin Liang, Lili Su, Wenjie You, Shujuan Jiang
Frontiers in Immunology.2023;[Epub] CrossRef
Immune-related adverse events induced by programmed death protein-1 inhibitors from the perspective of lymphoma immunotherapy
Yong-Zhe Hou, Qin Zhang, Hai Bai, Tao Wu, Ya-Jie Chen
World Journal of Clinical Cases.2023; 11(7): 1458. CrossRef
Predictive Biomarkers for Checkpoint Inhibitor Immune-Related Adverse Events
Iñigo Les, Mireia Martínez, Inés Pérez-Francisco, María Cabero, Lucía Teijeira, Virginia Arrazubi, Nuria Torrego, Ana Campillo-Calatayud, Iñaki Elejalde, Grazyna Kochan, David Escors
Cancers.2023; 15(5): 1629. CrossRef
Immune-related thyroid dysfunctions during anti PD-1/PD-L1 inhibitors: new evidence from a single centre experience
Alice Nervo, Matteo Ferrari, Giovanni Gruosso, Enrica Migliore, Sara Basile, Valentina D’Angelo, Anna Roux, Alessandro Piovesan, Emanuela Arvat
Clinical and Experimental Medicine.2023; 23(8): 4817. CrossRef
RNA Sequencing Reveals Unique Transcriptomic Signatures of the Thyroid in a Murine Lung Cancer Model Treated with PD-1 and PD-L1 Antibodies
Rena Pollack, Joshua Stokar, Natan Lishinsky, Irina Gurt, Naomi Kaisar-Iluz, Merav E. Shaul, Zvi G. Fridlender, Rivka Dresner-Pollak
International Journal of Molecular Sciences.2023; 24(13): 10526. CrossRef
Immune‐related adverse events after immune check point inhibitors: Understanding the intersection with autoimmunity
Namrata Singh, Anne M. Hocking, Jane H. Buckner
Immunological Reviews.2023; 318(1): 81. CrossRef
Endocrine Side Effects in Patients Treated with Immune Checkpoint Inhibitors: A Narrative Review
Nicia I. Profili, Roberto Castelli, Antonio Gidaro, Alessandro Merella, Roberto Manetti, Giuseppe Palmieri, Margherita Maioli, Alessandro P. Delitala
Journal of Clinical Medicine.2023; 12(15): 5161. CrossRef
Incidence of Endocrine-Related Dysfunction in Patients Treated with New Immune Checkpoint Inhibitors: A Meta-Analysis and Comprehensive Review
Won Sang Yoo, Eu Jeong Ku, Eun Kyung Lee, Hwa Young Ahn
Endocrinology and Metabolism.2023; 38(6): 750. CrossRef
PD-1/PD-L1 Inhibitors in Patients With Preexisting Autoimmune Diseases
Ke Zhang, Xiangyi Kong, Yuan Li, Zhongzhao Wang, Lin Zhang, Lixue Xuan
Frontiers in Pharmacology.2022;[Epub] CrossRef
Association between the type of thyroid dysfunction induced by immune checkpoint inhibitors and prognosis in cancer patients
Han-sang Baek, Chaiho Jeong, Kabsoo Shin, Jaejun Lee, Heysun Suh, Dong-Jun Lim, Moo Il Kang, Jeonghoon Ha
BMC Endocrine Disorders.2022;[Epub] CrossRef
A Successful Case of Hepatocellular Carcinoma Treated with Atezolizumab Plus Bevacizumab with Multisystem Immune-related Adverse Events
Hidemi Hayashi, Koji Sawada, Takumu Hasebe, Shunsuke Nakajima, Jun Sawada, Yuri Takiyama, Yumi Takiyama, Toshikatsu Okumura, Mikihiro Fujiya
Internal Medicine.2022; 61(23): 3497. CrossRef
Immune Related Adverse Events of the Thyroid – A Narrative Review
Christopher A. Muir, Venessa H. M. Tsang, Alexander M. Menzies, Roderick J. Clifton-Bligh
Frontiers in Endocrinology.2022;[Epub] CrossRef
Thyroid-related adverse events induced by immune checkpoint inhibitors
Alexandra Chera, Andreea Lucia Stancu, Octavian Bucur
Frontiers in Endocrinology.2022;[Epub] CrossRef
Risk Factors and Biomarkers for Immune-Related Adverse Events: A Practical Guide to Identifying High-Risk Patients and Rechallenging Immune Checkpoint Inhibitors
Adithya Chennamadhavuni, Laith Abushahin, Ning Jin, Carolyn J. Presley, Ashish Manne
Frontiers in Immunology.2022;[Epub] CrossRef
Case 5: A 41-Year-Old Woman With Palpitation
Jiwon Yang, Kabsoo Shin, Jeongmin Lee, Jeonghoon Ha, Dong-Jun Lim, Han-Sang Baek
Journal of Korean Medical Science.2022;[Epub] CrossRef
Immune Checkpoint Inhibitors and Endocrine Disorders: A Position Statement from the Korean Endocrine Society
Hyemi Kwon, Eun Roh, Chang Ho Ahn, Hee Kyung Kim, Cheol Ryong Ku, Kyong Yeun Jung, Ju Hee Lee, Eun Heui Kim, Sunghwan Suh, Sangmo Hong, Jeonghoon Ha, Jun Sung Moon, Jin Hwa Kim, Mi-kyung Kim
Endocrinology and Metabolism.2022; 37(6): 839. CrossRef
Management of Endocrine and Metabolic Toxicities of Immune-Checkpoint Inhibitors: From Clinical Studies to a Real-Life Scenario
Calogera Claudia Spagnolo, Giuseppe Giuffrida, Salvatore Cannavò, Tindara Franchina, Nicola Silvestris, Rosaria Maddalena Ruggeri, Mariacarmela Santarpia
Cancers.2022; 15(1): 246. CrossRef
Antineoplastics

Reactions Weekly.2021; 1874(1): 31. CrossRef

First
Prev
Page of 1
Next
Last

Search